| Accession |
PRJCA012884 |
| Title |
Phase III trial of pyrrotinib combined with trastuzumab plus docetaxel versus placebo combined with trastuzumab plus docetaxel in early or locally advanced HER2-positive breast cancer |
| Relevance |
Medical |
| Data types |
Clinical, imaging, biomarker data, etc
|
| Organisms |
Homo sapiens
|
| Description |
Phase III trial of pyrrotinib combined with trastuzumab plus docetaxel versus placebo combined with trastuzumab plus docetaxel in early or locally advanced HER2-positive breast cancer |
| Sample scope |
Multiisolate |
| Release date |
2022-10-31 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
NA
|
NA
|
NA
|
|
|
| Submitter |
weiqing ge
weiqing
ge (weiqing.ge@hengrui.com)
|
| Organization |
Jiangsu Hengrui pharmaceutical Co.LTD |
| Submission date |
2022-10-31 |
